Gene · 1871
Papers3,808
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,808
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring Key Biomarkers and Common Pathogenesis of Seven Digestive System Cancers and Their Correlation with COVID-19. | Curr Issues Mol Biol | 2023 | 37504265 | PubTator, text mining | PubMed |
| LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma. | J Ovarian Res | 2023 | 37501162 | PubTator, text mining | PubMed |
| E2F3 induces DNA damage repair, stem-like properties and therapy resistance in breast cancer. | Biochim Biophys Acta Mol Basis Dis | 2023 | 37499929 | PubTator, text mining | PubMed |
| The underlying molecular mechanisms and biomarkers between periodontitis and COVID-19. | BMC Oral Health | 2023 | 37495990 | PubTator, text mining | PubMed |
| Epstein-Barr virus microRNA miR-BART2-5p accelerates nasopharyngeal carcinoma metastasis by suppressing RNase Ⅲ endonuclease DICER1. | J Biol Chem | 2023 | 37495108 | PubTator, text mining | PubMed |
| Identification of the molecular subtypes and construction of risk models in neuroblastoma. | Sci Rep | 2023 | 37479876 | PubTator, text mining | PubMed |
| Helicobacter pylori-activated fibroblasts as a silent partner in gastric cancer development. | Cancer Metastasis Rev | 2023 | 37460910 | PubTator, text mining | PubMed |
| E2F3 accelerates the stemness of colon cancer cells by activating the STAT3 pathway. | Front Oncol | 2023 | 37456248 | PubTator, text mining | PubMed |
| A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses. | Front Oncol | 2023 | 37456238 | PubTator, text mining | PubMed |
| The role of long noncoding RNA H19 in gynecological pathologies: Insights into gene regulation and immune modulation (Review). | Int J Mol Med | 2023 | 37449492 | PubTator, text mining | PubMed |
| Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis. | Int J Mol Sci | 2023 | 37445988 | PubTator, text mining | PubMed |
| Small RNA Profiling in an HTLV-1-Infected Patient with Acute Adult T-Cell Leukemia-Lymphoma at Diagnosis and after Maintenance Therapy: A Case Study. | Int J Mol Sci | 2023 | 37445821 | PubTator, text mining | PubMed |
| MCF2L-AS1 promotes the biological behaviors of hepatocellular carcinoma cells by regulating the miR-33a-5p/FGF2 axis. | Aging (Albany NY) | 2023 | 37432067 | PubTator, text mining | PubMed |
| Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management. | Cancer Manag Res | 2023 | 37426392 | PubTator, text mining | PubMed |
| Retinoblastoma: A review of the molecular basis of tumor development and its clinical correlation in shaping future targeted treatment strategies. | Indian J Ophthalmol | 2023 | 37417104 | PubTator, text mining | PubMed |
| New insights on the interplays between m6A modifications and microRNA or lncRNA in gastrointestinal cancers. | Front Cell Dev Biol | 2023 | 37404673 | PubTator, text mining | PubMed |
| Upregulation of hsa_circ_0002003 promotes hepatocellular carcinoma progression. | BMC Cancer | 2023 | 37400785 | PubTator, text mining | PubMed |
| CDK4-E2F3 signals enhance oxidative skeletal muscle fiber numbers and function to affect myogenesis and metabolism. | J Clin Invest | 2023 | 37395281 | PubTator, text mining | PubMed |
| The role of EBV-encoded miRNA in EBV-associated gastric cancer. | Front Oncol | 2023 | 37388232 | PubTator, text mining | PubMed |
| Integrated Bioinformatics Investigation of Novel Biomarkers of Uterine Leiomyosarcoma Diagnosis and Outcome. | J Pers Med | 2023 | 37373974 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1871/papers?page=13